Biotech · Private company
Caliway Biopharmaceuticals Co., Ltd.
Track this companyFree. Adds Caliway Biopharmaceuticals Co., Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials113 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline13
- 0.9% Sodium ChloridePhase 3 · Subcutaneous FatClinicalTrials.gov · fetched Nov 12, 2026
- CBL-514 InjectionPhase 3 · Subcutaneous FatClinicalTrials.gov · fetched Nov 12, 2026
- 0.9% Sodium chloridePhase 2 · Dercum's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- 10 mg CBL-514 per injectionPhase 2 · Dercum's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- 15 mg CBL-514 per injectionPhase 2 · Dercum's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- 40 mg CBL-514Phase 2 · CelluliteClinicalTrials.gov · fetched Nov 12, 2026
- 60 mg CBL-514Phase 2 · CelluliteClinicalTrials.gov · fetched Nov 12, 2026
- 80 mg CBL-514Phase 2 · CelluliteClinicalTrials.gov · fetched Nov 12, 2026
- CBL-514Phase 2 · Subcutaneous FatClinicalTrials.gov · fetched Nov 12, 2026
- CBL-514 injectionPhase 2 · Dercum's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- CBL-514 injectionPhase 2 · CelluliteClinicalTrials.gov · fetched Nov 12, 2026
- CBL-A1 InjectionPhase 2 · Subcutaneous FatClinicalTrials.gov · fetched Nov 12, 2026
- CBL-A2 InjectionPhase 2 · Subcutaneous FatClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)PHASE3 · NOT_YET_RECRUITING · started Dec 1, 2026ClinicalTrials.gov NCT07733947 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )PHASE3 · NOT_YET_RECRUITING · started Oct 1, 2026ClinicalTrials.gov NCT07526974 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous FatPHASE3 · RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07140939 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease LipomasPHASE2 · COMPLETED · started Nov 27, 2024ClinicalTrials.gov NCT06303570 · fetched Nov 12, 2026
- A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.PHASE2 · COMPLETED · started Nov 10, 2023ClinicalTrials.gov NCT06005441 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous FatPHASE2 · COMPLETED · started May 30, 2023ClinicalTrials.gov NCT05736107 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)PHASE2 · COMPLETED · started May 10, 2023ClinicalTrials.gov NCT05836779 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)PHASE2 · COMPLETED · started Jan 9, 2023ClinicalTrials.gov NCT05632926 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease LipomasPHASE2 · COMPLETED · started Oct 3, 2022ClinicalTrials.gov NCT05387733 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)PHASE2 · COMPLETED · started Feb 14, 2022ClinicalTrials.gov NCT04897412 · fetched Nov 12, 2026
- A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy VolunteersPHASE2 · COMPLETED · started Feb 11, 2022ClinicalTrials.gov NCT05234736 · fetched Nov 12, 2026